Optimistic Buy Rating for Cullinan Management Driven by Promising Drug Pipeline and Upcoming Catalysts

Tip Ranks
2025.11.20 16:05
portai
I'm PortAI, I can summarize articles.

Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating for Cullinan Management, raising the price target to $26 due to promising drug pipeline developments and upcoming catalysts. The company, in collaboration with Taiho Oncology, is advancing a New Drug Application for zipalertinib, supported by positive trial results. Upcoming catalysts include Phase 1 results for CLN-049. Despite potential risks, the outlook remains optimistic. JonesTrading also maintained a Buy rating with a $34 target.

Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Cullinan Management, boosting the price target to $26.00.

TipRanks Black Friday Sale

  • Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
  • Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

Robert Burns has given his Buy rating due to a combination of factors including the promising progress of Cullinan Management’s drug development pipeline. The company, in collaboration with Taiho Oncology, has initiated a rolling submission for a New Drug Application (NDA) for zipalertinib, targeting a specific mutation in non-small cell lung cancer. This submission is backed by encouraging results from the REZILIENT1 trial, which demonstrated notable response rates in patients with prior treatments.
Furthermore, Burns highlights upcoming catalysts that could positively impact Cullinan’s valuation, such as the presentation of Phase 1 results for CLN-049 and the completion of the NDA for zipalertinib. The financial assessment using a discounted cash flow model, along with a high probability of approval for zipalertinib, supports the increased price target of $26 per share. Despite potential risks like trial enrollment delays or competitive pressures, the overall outlook remains optimistic, justifying the Buy recommendation.

In another report released on November 11, JonesTrading also maintained a Buy rating on the stock with a $34.00 price target.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.